Abstract
Reactive arthritis (ReA) is definitely caused by an infection. Several observations suggest that the triggering microbe may persist in the tissues of the patient for a prolonged time. The obvious conclusion is to consider antibacterial treatment. In two instances antibacterial agents are of definite value: in the primary and secondary prevention of rheumatic fever and for early eradication of Borrelia burgdorferi in order to prevent development of the arthritis associated with Lyme disease. Altogether, clinical and experimental data exist to indicate that if antibacterial treatment of ReA can be started very early during the pathogenetic process, the disease can be prevented or the prognosis improved. In fully developed ReA, the value of antibacterial agents is less certain. All available evidence indicates that short term antibacterial treatment has no effect on the prognosis and final outcome of ReA, and the results with long term administration of anti-bacterials are also overall poor. In some instances sulfasalazine appears useful, rather as a result of its antirheumatic effect or influence on an underlying inflammatory bowel disease than its action as an antibacterial agent. Tetracyclines have also been found to have an effect on ReA, but again, this is probably due to their anti-inflammatory action rather than any antibacterial effect.
Similar content being viewed by others
References
Toivanen P, Toivanen A. Two forms of reactive arthritis? Ann Rheum Dis 1999; 58: 737–41
Toivanen A, Toivanen P. Aetiopathogenesis of reactive arthritis. Rheumatol Europe 1995; 24: 5–8
Lahesmaa-Rantala R, Granfors K, Isomäki H, et al. Yersinia-specific immune complexes in the synovial fluid of patients with Yersinia-triggered reactive arthritis. Ann Rheum Dis 1987; 46: 510–4
Merilahti-Palo R, Söderström K-O, Lahesmaa-Rantala R, et al. Bacterial antigens in synovial biopsy specimens in yersinia-triggered reactive arthritis. Ann Rheum Dis 1991; 50: 87–90
Granfors K, Jalkanen S, von Essen R, et al. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med 1989; 320: 216–21
Gérard HC, Branigan PJ, Schumacher Jr HR, et al. Synovial Chlamydia trachomatis in patients with reactive arthritis/ Reiter’s syndrome are viable but show aberrant gene expression. J Rheumatol 1998; 25: 734–42
Hughes RA, Keat AC. Reiters syndrome and reactive arthritis: a current view. Semin Arthritis Rheum 1994; 24: 190–210
Hammer M, Nettelnbreker E, Hopf S, et al. Chlamydial rRNA in the joints of patients with chlamydia-induced arthritis and undifferentiated arthritis. Clin Exp Rheumatol 1992; 10: 63–6
Vilppula AH, Yli-Kerttula UI, Ahlroos AK, et al. Chlamydial isolations and serology in Reiter’s syndrome. Scand J Rheumatol 1981; 10: 181–5
Schachter J, Barnes MG, Jones JP, et al. Isolation of bedsoniae from the joints of patients with Reiters syndrome. Proc Soc Exp Biol Med 1996; 122: 283–5
Nikkari S, Rantakokko K, Ekman P, et al. Salmonella-triggered reactive arthritis: use of polymerase chain reaction, immuno-cytochemical staining, and gas chromatography-mass spectrometry in the detection of bacterial components from synovial fluid. Arthritis Rheum 1999; 42: 84–9
Ekman P, Nikkari S, Putto-Laurila A, et al. Detection of Salmonella infantis in synovial fluid cells of a patient with reactive arthritis. J Rheumatol 1999; 26: 2485–8
Toivanen A, Granfors K, Lahesmaa-Rantala R, et al. Pathogenesis of Yersinia-triggered reactive arthritis: immunological, microbiological and clinical aspects. Immunol Rev 1985; 86: 47–70
Hoogkamp-Korstanje JAA, de Koning J, Heesemann J. Persistence of Yersinia enterocolitica in man. Infection 1988; 16: 81–5
Weyand CM, Goronzy JJ. Clinically silent infections in patients with oligoarthritis: results of a prospective study. Ann Rheum Dis 1992; 51: 253–8
Sairanen E, Paronen I, Mähönen H. Reiter’s syndrome: a follow-up study. Acta Med Scand 1969; 185: 57–63
Kvien TK, Glennås A, Melby K, et al. The natural history of reactive arthritis. Rheumatol Europe 1995; 24: 15–9
Leirisalo-Repo M, Suoranta H. Ten-year follow-up study of patients with Yersinia arthritis. Arthritis Rheum 1988; 31: 533–7
Leirisalo-Repo M, Helenius P, Hannu T, et al. Long term prognosis of reactive salmonella arthritis. Ann Rheum Dis 1997; 56: 516–20
Mielants H, Veys EM. The gut and reactive arthritis. Rheumatol Europe 1995; 24: 9–11
Yli-Kerttula T, Möttönen T, Toivanen A. Different course of reactive arthritis in two HLA-B27 positive brothers with fatal outcome in one. J Rheumatol 1997; 24: 2047–50
Konttinen YT, Nordström DC, Bergroth V, et al. Occurrence of different ensuing triggering infections preceding reactive arthritis: a follow up study. BMJ 1988; 296: 1644–5
Jansen TL, Janssen M, van Riel PLCM. Acute rheumatic fever or post-streptococcal reactive arthritis: a clinical problem revisited. Br J Rheumatol 1998; 37: 335–40
Jansen TL, Janssen M, Traksel R, et al. A clinical and serological comparison of group A versus non-group A streptococcal reactive arthritis and throat culture negative cases of post-streptococcal reactive arthritis. Ann Rheum Dis 1999; 58: 410–4
Ahmed S, Ayoub EM, Scornik JC, et al. Poststreptococcal reactive arthritis: clinical characteristics and association with HLA-DR alleles. Arthritis Rheum 1998; 41: 1096–102
Mason T, Fisher M, Kujala G. Acute rheumatic fever in West Virginia: not just a disease of children. Arch Intern Med 1991; 151: 133–6
Amigo M-C, Martínez-Lavín M, Reyes PA. Acute rheumatic fever. Rheum Dis Clin North Am 1993; 19: 333–50
Feuer J, Spiera H. Acute rheumatic fever in adults: a resurgence in the Hasidic Jewish community. J Rheumatol 1997; 24: 337–40
Bisno AL. Group a streptococcal infections and acute rheumatic fever. N Engl J Med 1991; 325: 783–93
Lue HC, Wu MH, Wang JK, et al. Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks. J Pediatr 1994; 125: 812–6
Jansen TL, Janssen M, de Jong AJ, et al. Post-streptococcal reactive arthritis: a clinical and serological description, revealing its distinction from acute rheumatic fever. J Intern Med 1999; 245: 261–7
Magid D, Schwartz B, Graft J, et al. Prevention of Lyme disease after tick bites. N Engl J Med 1992; 327: 534–41
Weber K, Pfister H-W. Clinical management of Lyme borreliosis. Lancet 1994; 343: 1017–20
Weyand CM, Goronzy JJ. Immune responses to Borrelia burgdorferi in patients with reactive arthritis. Arthritis Rheum 1989; 32: 1057–64
Gross DM, Forsthuber T, Tary-Lehman M, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998; 281: 703–6
Preac-Mursic V, Weber K, Pfister HW, et al. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection 1989; 17: 355–9
Steere AC, Dwyer E, Winchester R. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. N Engl J Med 1990; 323: 219–23
Hoogkamp-Korstanje JAA, de Koning J, Heesemann J, et al. Influence of antibiotics on IgA and IgG response and persistence of Yersinia enterocolitica in patients with Yersinia-associated spondylarthropathy. Infection 1992; 20: 53–7
Frydén A, Bengtsson A, Foberg U, et al. Early antibiotic treatment of reactive arthritis associated with enteric infections: clinical and serological study. BMJ 1990; 301: 1299–302
Locht H, Kihlström E, Lindström FD. Reactive arthritis after Salmonella among medical doctors: study of an outbreak. J Rheumatol 1993; 20: 845–8
Mattila L, Leirisalo-Repo M, Pelkonen P, et al. Reactive arthritis following an outbreak of Salmonella bovismorbificans infection. J Infection 1998; 36: 289–95
Popert AJ, Gill AJ, Laird SM. A prospective study of Reiter’s syndrome: an interim report on the first 82 cases. Br J Vener Dis 1964; 40: 160–5
Bardin T, Schumacher HR. Should we treat postvenereal Reiters syndrome by antibiotics? J Rheumatol 1991; 18: 1780–2
Bardin T, Enel C, Cornells F, et al. Antibiotic treatment of venereal disease and Reiter’s syndrome in a Greenland population. Arthritis Rheum 1992; 35: 190–4
Panayi GS, Clark B. Minocycline in the treatment of patients with Reiter’s syndrome. Clin Exp Rheumatol 1989; 7: 100–1
Lauhio A, Leirisalo-Repo M, Lähdevirta J, et al. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 1991; 34: 6–14
Lauhio A, Sorsa T, Lindy O, et al. The anticollagenolytic potential of lymecycline in the long-term treatment of reactive arthritis. Arthritis Rheum 1992; 35: 195–8
Wollenhaupt J, Hammer M, Pott HG, et al. A double-blind, placebo-controlled comparison of 2 weeks versus 4 months treatment with doxycycline in Chlamydia-induced reactive arthritis. Arthritis Rheum 1997; 40: S143
Beutler AM, Hudson AP, Whittum-Hudson JA, et al. Chlamydia trachomaiis can persist in joint tissue after antibiotic treatment in chronic Reiters syndrome/reactive arthritis. J Clin Rheumatol 1997; 3: 125–30
Sieper J, Fendler C, Laitko S, et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis. Arthritis Rheum 1999; 42: 1386–96
Toivanen A, Yli-Kerttula T, Luukkainen R, et al. Effect of antimicrobial treatment on chronic reactive arthritis. Clin Exp Rheumatol 1993; 11: 301–7
Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, et al. Effect of a three-month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis 2000; 59: 565–70
Wakefield D, McCluskey P, Verma M, et al. Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis. Arthritis Rheum 1999; 42: 1894–7
Sieper J, Braun J. Treatment of reactive arthritis with antibiotics. Br J Rheumatol 1998; 37: 717–20
Toivanen A, Möttönen T. Ankylosing spondylitis: current approaches to treatment. BioDrugs 1998; 10: 193–200
Mielants H, Veys EM. HLA-B27 related arthritis and bowel inflammation. Part 1. Sulphasalazine (Salazopyrin) in HLA-B27 related reactive arthritis. J Rheumatol 1985; 12: 287–93
Mielants H, Veys EM, Joos R. Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis. Clin Rheumatol 1986; 5: 80–3
Trnavský K, Pelišková Z, Vácha J. Sulphasalazine in the treatment of reactive arthritis. Scand J Rheumatol 1988; 67: 76–9
Youssef PP, Bertouch JV, Jones PD. Successful treatment of human immunodeficiency virus-associated Reiters syndrome with sulfasalazine. Arthritis Rheum 1992; 35: 723–4
Egsmose C, Hansen TM, Andersen LS, et al. Limited effect of sulphasalazine treatment in reactive arthritis: a randomised double-blind placebo-controlled trial. Ann Rheum Dis 1997; 56: 32–6
Clegg DO, Reda DJ, Abdellatif M. Comparison of sulphasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylar-thropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999; 42: 2325–9
Breban M, Fournier C, Gougerot-Pocidalo M-A et al. Protective effects of ciprofloxacin against type II collagen induced arthritis in rats. J Rheumatol 1992; 19: 216–22
Toivanen A, Merilahti-Palo R, Gripenberg C, et al. Yersinia-associated arthritis in the rat: experimental model for human reactive arthritis? Acta Pathol Microbiol Immunol Scand (C) 1986; 94: 261–9
Merilahti-Palo R, Gripenberg-Lerche C, Söderström K-O, et al. Long term follow up of SHR rats with experimental yersinia-associated arthritis. Ann Rheum Dis 1992; 51: 91–6
Zhang Y, Gripenberg-Lerche C, Söderström K-O, et al. Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model. Arthritis Rheum 1996; 39: 1238–43
Zhang Y, Toivanen A, Toivanen P. Experimental Yersinia-triggered reactive arthritis; effect of a 3-week course with ciprofloxacin. Br J Rheumatol 1997; 36: 541–6
Acknowledgements
The support of a Turku University Central Hospital EVO-grant is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Toivanen, A. Bacteria-Triggered Reactive Arthritis. Drugs 61, 343–351 (2001). https://doi.org/10.2165/00003495-200161030-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200161030-00003